14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HHS vs DLX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Deluxe Corporation (DLX) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas DLX carries 31.4/100 (SELL) at $27.05 (6.5x Forward P/E, 12.8% operating margin).
Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. DLX 31.4/100 SELL), DLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.8% vs. -3.2% operating margin) and revenue trajectory (+2.5% vs. -1.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs DLX. Trailing 12-month operating profitability (HHS -3.2% vs DLX 12.8%) and valuation multiples (HHS 14.3x vs DLX 6.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Conglomerates value chain with $1.2B market capitalization and 12.8% operating margin.
OpEx & R&D Reinvestment39.3% of Rev ($836M)
90D Engineering Disclosures0 Published
Investor FAQ HHS vs DLX Key Questions & Quantitative Answers
As of Nov 16, 2026, Deluxe Corporation (DLX) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas DLX carries 31.4/100 (SELL) at $27.05 (6.5x Forward P/E, 12.8% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. DLX 31.4/100 SELL), DLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.8% vs. -3.2% operating margin) and revenue trajectory (+2.5% vs. -1.7% YoY).
DLX leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with DLX at +2.5% YoY revenue growth and -62.2% YoY earnings growth on $2.13B TTM revenue (52.1% gross margin, 12.8% operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus $2.13B for DLX. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 39.3% of Rev ($836M) (0 disclosures) for DLX.
DLX screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas DLX trades at 6.5x Forward P/E, 15.5x Trailing P/E, 0.53x PEG, and 0.6x EV/Revenue (20.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus DLX (11.6% ROE) capital efficiency.
In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, DLX carries 24.9% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.45β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.